Loading...
Background: Telithromycin (Ketek) is the first of the ketolides -- a new family of antibiotics closely related to the macrolides -- to reach clinical use. It received FDA approval in April 2004 for treatment of community-acquired respiratory tract infections (i.e., acute bacterial exacerbations of chronic bronchitis, acute bacterial sinusitis, and mild-to-moderate pneumonia) in adults.
At the concentrations usually achieved after oral administration, telithromycin is bactericidal, with a significant postantibiotic effect lasting as long as 9 hours. Telithromycin binds to the same domains of the 50S subunit of bacterial ribosomes as do macrolides, albeit -- in wild-type isolates -- 6 times more tightly than clarithromycin and 10 times more ti…